References
- Schifano F, Orsolini L, Papanti GD, et al. Novel psychoactive substances of interest for psychiatry. World Psychiatry. 2015;14:15–26.
- Orsolini L, Papanti GD, Francesconi G, et al. Mind navigators of chemicals’ experimenters? A web-based description of e-psychonauts. Cyberpsychol Behav Soc Netw. 2015;18:296–300.
- Deluca P, Davey Z, Corazza O, et al. Identifying emerging trends in recreational drug use; outcomes from the Psychonaut Web Mapping Project. Prog Neuropsychopharmacol Biol Psychiatry. 2012;39:221–226.
- Simmler LD, Buser TA, Donzelli M, et al. Pharmacological characterization of designer cathinones in vitro. Br J Pharmacol. 2013;168:458–470.
- De Felice LJ, Glennon RA, Negus SS. Synthetic cathinones: Chemical phylogeny, physiology, and neuropharmacology. Life Sci. 2014;97(1):20–26.
- Baumann MH, Ayestas MA Jr, Partilla JS, et al. The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue. Neuropsychopharmacol. 2012;37:1192–1203.
- Baumann MH, Partilla JS, Lehner KR, et al. Powerful cocaine-like actions of 3,4-methylenedioxypyrovalerone (MDPV), a principal constituent of psychoactive ‘bath salts’ products. Neuropsychopharmacol. 2013;38:552–562.
- Gregg RA, Rawls SM. Behavioral pharmacology of designer cathinones: a review of the preclinical literature. Life Sci. 2014;97(1):27–30.
- Iversen L, White M, Treble R. Designer psychostimulants: pharmacology and differences. Neuropharmacology. 2014;87:59–65.
- Abdulrahim D, Bowden-Jones O, on behalf of the NEPTUNE Expert Group. Guidance on the management of acute and chronic harms of club drugs and novel psychoactive substances. London: Novel Psychoactive Treatment UK Network; 2015 [cited 2016 Feb 14]. Available from: http://neptune-clinical-guidance.co.uk/wp-content/uploads/2015/03/NEPTUNE-Guidance-March-2015.pdf
- Farrè M, Papaseit E, Pérez-Mañá C, et al. Human pharmacology of mephedrone: a dose-finding pilot study. San Juan: College on Problems of Drug Dependence Meeting; 2014.
- Schifano F. Novel psychoactive substances also known as ‘legal highs’. Annual report of the Chief Medical Officer 2013. Public mental health priorities: investing in the evidence. London: Department of Health; 2014 [cited 2015 Nov 22]. Available from: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/413196/CMO_web_doc.pdf
- Schifano F, Corkery J, Ghodse AH. Suspected and confirmed fatalities associated with mephedrone (4-methylmethcathinone; ‘meow meow’) in the UK. J Clin Psychopharmacol. 2012;32:710–714.
- Corkery JM, Schifano F, Ghodse AH. Mephedrone-related fatalities in the United Kingdom: contextual, clinical and practical issues. Pharmacology. Rijeka (Croatia): InTech - Open Access Publisher; 2012 [cited 2015 Nov 15]. http://www.intechopen.com/books/pharmacology/mephedrone-related-fatalities-in-the-united-kingdom-contextual-clinical-and-practical-issues: Available from.
- Corkery JM, Schifano F, Oyefeso A, et al. ‘Bundle of fun’ or ‘bunch of problems’? Case series of khat-related deaths in the UK. Drugs: Educ Prev Polic. 2011;18:408–425.
- Loi B, Corkery JM, Claridge H, et al. Deaths of individuals aged 16-24 years in the UK after using mephedrone. Hum Psychopharmacol. 2015;30:225–232.
- Schifano F, Albanese A, Fergus S, et al. Psychonaut Web Mapping; ReDNet Research Groups. Mephedrone (4-methylmethcathinone; ‘meow meow’): chemical, pharmacological and clinical issues. Psychopharmacol. 2011;214:593–602.
- EMCDDA. Perspectives on drugs: injection of synthetic cathinones. Perspectives on Drugs Series. Lisbon: European Monitoring Centre for Drugs and Drug Addiction; 2014 [cited 2015 Nov 30]. Available from: http://www.emcdda.europa.eu/topics/pods/synthetic-cathinones-injection.
- Giese C, Igoe D, Gibbons Z, et al. Injection of new psychoactive substance snow blow associated with recently acquired HIV infections among homeless people who inject drugs in Dublin, Ireland, 2015. Euro Surveill. 2015;20(40). doi:10.2807/1560-7917.ES.2015.20.40.30036.
- Bourne A, Reid D, Hickson F, et al. The Chemsex study: drug use in sexual settings among gay & bisexual men in Lambeth, Southwark & Lewisham. London: Sigma Research, London School of Hygiene & Tropical Medicine; 2014 [cited 2015 Nov 30]. Available from: https://www.lambeth.gov.uk/sites/default/files/ssh-chemsex-study-final-main-report.pdf
- ONS. Deaths related to drug poisoning in England and Wales, 2014 registrations release. Newport (Gwent): Office for National Statistics. 2015 [cited 2015 Nov 30]. Available from:http://www.ons.gov.uk/ons/dcp171778_414574.pdf
- EMCDDA. EMCDDA–Europol Joint Report on a new psychoactive substance: 4,4′-DMAR (4-methyl-5-(4-methylphenyl)-4,5- dihydrooxazol-2-amine). Luxembourg: European Monitoring Centre for Drugs and Drug Addiction; 2014 [cited 2016 March 13]. Available from: http://www.emcdda.europa.eu/attachements.cfm/att_229825_EN_TDAS14006ENN.pdf
- ACMD. Methylphenidate-based NPS: a review of the evidence of use and harm. 2015 [cited 2016 Jan 17] Available from: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/420983/TCDO_methylphenidate_NPS.pdf
- Wedinos. 2016 [cited 2016 Jan 17]. Available from: http://www.wedinos.org/db/samples/search.
- TripSit. 2016 [cited 2016 Jan 17]. Available from: http://drugs.tripsit.me/ethylphenidate
- PsychonautWiki. 2016 [cited 2016 Jan 17]. Available from: https://psychonautwiki.org/wiki/Ethylphenidate.
- Ho JH, Bailey GP, Archer JR, et al. Ethylphenidate: availability, patterns of use, and acute effects of this novel psychoactive substance. Eur J Clin Pharmacol. 2015;71:1185–1196.
- Soussan C, Kjellgren A. “Chasing the high” - experiences of ethylphenidate as described on international internet forums. Subst Abuse. 2015;9:9–16.
- EMCDDA. New psychoactive substances in Europe - An update from the EU Early Warning System. Luxembourg: European Monitoring Centre for Drugs and Drug Addiction. Publications Office of the European Union; 2015 [cited 2015 Nov 15]. Available from: http://www.emcdda.europa.eu/publications/2015/new-psychoactive-substances.
- Barratt MJ, Allen M, Lenton S. “PMA sounds fun”: negotiating drug discourses online. Subst Use Misuse. 2014;49:987–998.
- Di Renzo G, Amoroso S, Taglialatela M, et al. Pure uptake blockers of dopamine can reduce prolactin secretion: studies with diclofensine. Life Sci. 1988;42:2161–2169.
- Nakachi N, Kiuchi Y, Inagaki M, et al. Effects of various dopamine uptake inhibitors on striatal extracellular dopamine levels and behaviours in rats. Eur J Pharmacol. 1995;281:195–203.
- Blicke FF, Burckhalter JH. α-Thienylaminoalkanes. J Am Chem Soc. 1942;64:477–480.
- Angelov D, O’Brien J, Kavanagh P. The syntheses of 1-(2-thienyl)-2-(methylamino) propane (methiopropamine) and its 3-thienyl isomer for use as reference standards. Drug Test Anal. 2013;5:145–149.
- Bouso ED, Gardner EA, O’Brien JE, et al. Characterization of the pyrolysis products of methiopropamine. Drug Test Anal. 2013;6:676–683.
- Erowid.org. 2014 [cited 2014 Sep 28]. Available from: www.erowid.org.
- Iversen L, Gibbons S, Treble R, et al. Neurochemical profiles of some novel psychoactive substances. Eur J Pharmacol. 2013;700:147–151.
- UNODC. Aminoindanes. 2015 [cited 2016 Feb 7]. Available from: https://www.unodc.org/LSS/SubstanceGroup/Details/8fd64573-c567-4734-a258-76d1d95dca25.
- Johnson MP, Frescas SP, Oberlender R, et al. Synthesis and pharmacological examination of 1-(3-methoxy-4-methylphenyl)-2-aminopropane and 5-methoxy-6-methyl-2-aminoindan: similarities to 3,4-(methylenedioxy)methamphetamine (MDMA). J Med Chem. 1991;34:1662–1668.
- Monte AP, Marona-Lewicka D, Cozzi NV, et al. Synthesis and pharmacological examination of benzofuran, indan, and tetralin analogues of 3,4-(methylenedioxy)amphetamine. J Med Chem. 1993;36:3700–3706.
- Dargan PI, Wood DM. Novel psychoactive substances: classification, pharmacology and toxicology. London: Academic Press/Elsevier; 2013.
- Corkery JM, Elliott S, Schifano F, et al. MDAI (5,6-methylenedioxy-2-aminoindane; 6,7-dihydro-5H-cyclopenta[f][1,3]benzodioxol-6-amine; ‘sparkle’; ‘mindy’) toxicity: a brief overview and update. Hum Psychopharmacol. 2013;28:345–355.
- Carroll FI, Gao Y, Rahman P, et al. Synthesis, ligand binding, QSAR, and CoMFA study of 3b-(p-substituted phenyl)tropane- 2b-carboxylic acid methyl esters. J Med Chem. 1991;34:2719–2725.
- Fleckenstein AE, Kopajtic TA, Boja JW, et al. Highly potent cocaine analogs cause long-lasting increases in locomotor activity. Eur J Pharmacol. 1996;311:109–114.
- Carroll FI, Blough BE, Nie Z, et al. Synthesis and monoamine transporter binding properties of 3-(3ʹ,4ʹ-disubstituted phenyl)- tropane-2-carboxylic acid methyl esters. J Med Chem. 2005;48:2767–2771.
- Papanti D, Orsolini L, Francesconi SF. ‘Noids’ in a nutshell: everything you (don’t) want to know about synthetic cannabimimetics. Adv Dual Diagn. 2014;7:137–148.
- De Luca MA, Castelli MP, Loi B, et al. Native CB1 receptor affinity, intrisic activity and accumbens shell dopamine stimulant properties of third generation SPICE/K2 cannabinoids: BB-22, 5F-PB-22, 5F-AKB-48 and STS-135. Neuropharmacology. 2015. Published online 2015 Dec 11. doi:10.1016/j.neuropharm.2015.11.017.
- Brents LK, Prather PL. The K2/Spice Phenomenon: emergence, identification, legislation and metabolic characterization of synthetic cannabinoids in herbal incense products. Drug Metab Rev. 2014;46:72–85.
- Fišar Z. Cannabinoids and monoamine neurotransmission with focus on monoamine oxidase. Prog Neuropsychopharmacol Biol Psychiatry. 2012;38:68–77.
- Franklin JM, Carrasco GA. Cannabinoid receptor agonists upregulate and enhance serotonin 2A (5-HT(2A)) receptor activity via ERK1/2 signaling. Synapse. 2013;67:145–159.
- Morgan D, Kondabolu K, Kuipers A, et al. Molecular and behavioral pharmacology of two novel orally-active 5HT2 modulators: potential utility as antipsychotic medications. Neuropharmacology. 2013;72:274–281.
- Daly M. Streets legal. Druglink. 2013;28:17.
- Schifano F, Corazza O, Davey Z, et al. Psychoactive drug or mystical incense? Overview of the online available information on Spice products. Int J Cult Ment Health. 2009;2:137–144.
- Martinotti G, Lupi M, Acciavatti A, et al. Novel psychoactive substances in young adults with and without psychiatric comorbidities. Biomed Res Int. 2014;2014:1–7. Published online 2014 Jul 15. doi:10.1155/2014/815424.
- Fantegrossi WE, Moran JH, Radominska-Pandya A, et al. Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to Δ(9)-THC: mechanism underlying greater toxicity? Life Sci. 2014;97:45–54.
- Papanti D, Schifano F, Botteon G, et al. ‘Spiceophrenia’: A systematic overview of ‘Spice’–related psychopathological issues and a case report. Hum Psychopharmacol. 2013;28:379–389.
- Ustundag MF, Ozhan Ibis E, Yucel A, et al. Synthetic cannabis-induced mania. Case Rep Psychiatry. 2015;2015:1–3. Published online 2015 Mar 9. doi:10.1155/2015/310930.
- Kroll D. Scientists speculate on what caused the bial drug testing tragedy in France. Forbes. 2016 [cited 2016 Jan 31]. Available from: http://www.forbes.com/sites/davidkroll/2016/01/18/scientists-speculate-on-what-caused-the-bial-drug-testing-tragedy-in-france/#44142708301f.
- Shulgin AT, Manning T, Daley PF. The shulgin index, volume one: psychedelic phenethylamines and related compounds. Berkeley: Transform Press; 2011.
- Corazza O, Schifano F, Farre M, et al. Designer drugs on the internet: a phenomenon out-of-control? the emergence of hallucinogenic drug Bromo-Dragonfly. Curr Clin Pharmacol. 2011;6:125–129.
- O’Connor RE, Keating JJ. Characterization of synthetic routes to ‘Bromo-DragonFLY’ and benzodifuranyl isopropylamine homologues utilizing ketone intermediates. Part 1: synthesis of ketone precursors. Drug Test Anal. 2014;6:658–667.
- Rickli A, Hoener MC, Liechti ME. Monoamine transporter and receptor interaction profiles of novel psychoactive substances: para-halogenated amphetamines and pyrovalerone cathinones. Eur Neuropsychopharmacol. 2015;25:365–376.
- Bersani FS, Corazza O, Albano G, et al. 25C-NBOMe: preliminary data on pharmacology, psychoactive effects and toxicity of a new potent and dangerous hallucinogenic drug. Biomed Res Int. 2014. Published online 2014 Jul 3. doi:10.1155/2014/734749.
- Wood DM, Sedefov R, Cunningham A, et al. Prevalence of use and acute toxicity associated with the use of NBOMe drugs. Clin Toxicol (Phila). 2015;53:85–92.
- Braden MR, Parrish JC, Naylor JC, et al. Molecular interaction of serotonin 5-HT2A receptor residues Phe339(6.51) and Phe340(6.52) with superpotent N-benzyl phenethylamine agonists. Mol Pharmacol. 2006;70:1956–1964.
- Lowe LM, Peterson BL, Couper FJ. A case review of the first analytically confirmed 25I-NBOMe-related death in Washington state. J Anal Toxicol. 2015;39:668–671.
- Jebadurai J, Schifano F, Deluca P. Recreational use of 1-(2-naphthyl)-2-(1-pyrrolidinyl)-1-pentanone hydrochloride (NRG-1), 6-(2-aminopropyl) benzofuran (benzofury/6-APB) and NRG-2 with review of available evidence-based literature. Hum Psychopharmacol. 2013;28:356–364.
- Elliott S, Evans J. A 3-year review of new psychoactive substances in casework. Forensic Sci Int. 2014;243:55–60.
- AMCD. Update of the Generic Definition for Tryptamines. 2014 [cited 2016 Feb 13]. Available from: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/318693/UpdateGenericDefinitionTryptamines.pdf
- Collins M. Some new psychoactive substances: precursor chemicals and synthesis-driven end-products. Drug Test Anal. 2011;3:404–416.
- Pierce PA, Peroutka SJ. Hallucinogenic drug interactions with neurotransmitter receptor binding sites in human cortex. Psychopharmacol. 1989;97:118–122.
- Shulgin AT, Shulgin A. TIHKAL: the continuation. Berkeley: Transform Press; 1997.
- Araújo AM, Carvalho F, de Lourdes Bastos M, et al. The hallucinogenic world of tryptamines: an updated review. Arch Toxicol. 2015;89:1151–1173.
- Halpern JH. Hallucinogens and dissociative agents naturally growing in the United States. Pharmacol Ther. 2004;102:131–138.
- Peden NR, Macaulay KEC, Bisset AF, et al. Clinical toxicology of ‘magic mushroom’ ingestion. Postgrad Med J. 1981;57:543–545.
- Hill SL, Thomas SH. Clinical Toxicology of newer recreational drugs. Clin Toxicol. 2011;49:705–719.
- Lyttle T, Goldstein D, Gartz J. Bufo. Toads and bufotenine: fact and fiction surrounding an alleged psychedelic. J Psychoactive Drugs. 1996;28:267–290.
- Ujváry I. Psychoactive natural products: overview of recent developments. Ann Ist Super Sanità. 2014;50:12–27.
- Nagai F, Nonaka R. Satoh Hisashi Kamimura K. The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain. Eur J Pharmacol. 2007;559:132–137.
- Schifano F. Novel psychoactive substances (NPS): clinical and pharmacological issues. Drugs Alcohol Today. 2015;15:21–27.
- Velez L, Benitez F. New troublesome drugs: the synthetics. [cited 2016 Feb 4]. Available from: http://www.emdocs.net/new-troublesome-drugs-the-synthetics.
- Guirguis A, Corkery JM, Stair JL, et al. Survey of knowledge of legal highs (novel psychoactive substances) amongst London pharmacists. Drugs Alcohol Today. 2015;15:93–99.